Biosimilars may be a roaring success in Europe but the picture in the U.S. couldn’t be more different. Once hailed as a solution to stem the tide of soaring drug spending, in the cold light of day, the U.S. biosimilars market has failed to meet expectations. Payers are frustrated. Can the cycle of endless litigation and aggressive commercial tactics be broken? How are payers coping? What do these key stakeholders need to happen next?
Our professional researchers have just interviewed 10 senior level payers, raising the key issues from the last 12 months and revealing their views on potential market evolution.
- Is the U.S. biosimilars regulatory framework fit for purpose? How will recent reforms make a difference?
- Which events of the last year have hampered the biosimilars market the most – and why?
- What more must be done to build critical awareness, understanding and confidence?
- To switch or not to switch to biosimilars? What drives non-clinical switching decisions?
- Is clinical confidence a real or perceived issue? Is more real-world evidence the answer?
- Are payers for or against pharmacy-level substitution?
- Will payers assume interchangeability in order to drive better biosimilar adoption rates?
- Which utilisation management tactics are used to boost biosimilar use? And should branded products be excluded from formularies?
- What is the payers’ perspective on the 3 biosimilars currently in use?
- How do payers predict future launches will go?
